Stockpolly
Search
HURA · NASDAQ · Biotechnology

TuHURA Biosciences (HURA)

Develops immunotherapies aimed at overcoming resistance to cancer treatment.

$2.08
At close+0.05 (+2.46%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
3152467107889
Research & development204034555657
111212212−222
General & administrative001000212−222
Other expenses000000040400
Operating income−3−1−5−2−4−6−7−10−7−8−8−9
0000−20000100
Interest income000000000000
Interest expense000121000100
Other non-operating income000000000−200
Income before tax−3−1−5−2−6−6−7−10−7−7−8−9
Net income from continuing operations−3−1−5−2−6−6−7−10−7−7−8−9
Net income−3−1−5−2−6−6−7−10−7−7−8−9
EPS, basic−$63.91−$8.27−$0.40−$1.47−$3.00−$0.14−$0.15−$0.21−$0.14−$0.13−$0.13−$0.14
EPS, diluted−$63.91−$8.27−$0.40−$1.47−$3.00−$0.14−$0.15−$0.21−$0.14−$0.13−$0.13−$0.14
Weighted average shares, basic00122242434551486064
Weighted average shares, diluted00122242434551486064
EBITDA−3−1−5−2−4−5−7−10−7−6−7−9
Depreciation & amortization000000000000
EBIT−3−1−5−2−4−5−7−10−7−6−8−9